Claims for Patent: 10,266,586

Summary for Patent: 10,266,586

Title:	Targeting CLPTM1L for treatment and prevention of cancer
Abstract:	Provided herein are therapeutic agents having specificity for human CLPTM1 L polypeptide, including therapeutic agents comprising one or more CLPTM1 L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1 L protein dysfunction (e.g., pathogenic production, modification, or function).
Inventor(s):	James; Michael A. (Big Bend, WI)
Assignee:	The Medical College of Wisconsin, Inc. (Milwaukee, WI)
Application Number:	15/111,445
Patent Claims:	1. A CLPTM1L-targeting agent, wherein the CLPTM1L-targeting agent is a monoclonal antibody specific for at least a portion of a CLPTM1L polypeptide and selected from anti-CLPTM1L monoclonal antibody clones 6-1 (ATCC PTA-125531), 10-2 (ATCC PTA-125532), and 10-3(ATCC PTA-125530). 2. A pharmaceutical composition comprising the CLPTM1L-targeting agent of claim 1 and a pharmaceutically acceptable carrier. 3. An article of manufacture comprising: (a) the pharmaceutical composition of claim 2, and (b) an insert providing instructions for treating a solid tumor in a human subject. 4. A method for treating a lung cancer comprising administering a therapeutically effective amount of a compound comprising a CLPTM1L-targeting agent to a subject in need thereof, wherein the CLPTM1L-targeting agent is a monoclonal antibody specific for at least a portion of a CLPTM1L polypeptide and selected from anti-CLPTM1L monoclonal antibody clones 6-1 (ATCC PTA-125531), 10-2 (ATCC PTA-125532), and 10-3 (ATCC PTA-125530), whereby the lung cancer is treated in the subject. 5. The method of claim 4, wherein the subject is a human. 6. The method of claim 4, wherein the lung cancer exhibits resistance to a chemotherapeutic agent. 7. The method of claim 6, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, gemcitabine, carboplatin, carmustine, methotrexate, fluorouracil, goserelin, leuprolide, tamoxifen, docetaxel, paclitaxel, aldesleukin, interleukin-2, etoposide (VP-16), interferon-alpha, tretinoin (ATRA), bleomycin, dactinomycin, daunorubicin, doxorubicin, mitomycin, vinblastine, and vincristine. 8. The method of claim 4, wherein the compound is administered with a pharmaceutically acceptable carrier.

Details for Patent 10,266,586

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2034-01-14